Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial


Por: Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y and Rosell, R

Publicada: 1 abr 2026 Ahead of Print: 1 mar 2026
Resumen:
Background Fulzerasib, a KRASG12C inhibitor, has shown clinical activity in previously treated non-small-cell lung cancer (NSCLC). Clinical studies indicate that combining a KRASG12C inhibitor with an anti-EGFR antibody is effective in colorectal cancer; however, its benefit in NSCLC remains to be explored. Methods This single-arm, phase 1b/2 trial enrolled patients at 30 medical centres in Spain, Italy, and Greece. Eligible patients had KRASG12C-mutated NSCLC with no previous systemic anti-tumour therapy for advanced or metastatic disease and were aged 18 years and older; had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1; had an Eastern Cooperative Oncology Group performance status of 0 or 1; and had a life expectancy of 3 months or more. Enrolled patients received 600 mg oral fulzerasib twice daily plus 500 mg/m2 intravenous cetuximab every 2 weeks. The primary endpoint was investigator-assessed objective response rate per RECIST 1.1 assessed in the full response analysis set. The study was registered with ClinicalTrials.gov (NCT05756153) and is complete. Findings Between April 23, 2023, and April 15, 2024, a total of 60 patients were screened, and 47 patients (78%) received treatment. The median age was 68 years (IQR 59-72); 25 patients (53%) were male and 22 (47%) were female. 45 (95%) patients were current or former smokers. As of Jan 14, 2025, the median follow-up time and treatment duration were 12 & centerdot;8 months (90% CI 11 & centerdot;6-14 & centerdot;6) and 10 & centerdot;1 months (IQR 6 & centerdot;3-13 & centerdot;0) months, respectively. The confirmed objective response rate was 69% (90% CI 56-80). Treatment-related adverse events (TRAEs) occurred in 41 (87%) of the 47 patients (grade 3 in seven [15%]). No grade 4 or 5 TRAEs were observed. TRAEs led to drug discontinuation in three (6%) patients, with only cetuximab being discontinued. Interpretation In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study. Funding Zhejiang GenFleet Therapeutics. Copyright (c) 2026 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Filiaciones:
Gregorc, V:
 Ist Candiolo Fdn Piemonte Oncol IRCCS, Candiolo, Italy

Majem, M:
 Hosp Santa Creu & St Pau, Barcelona, Spain

Lo Russo, G:
 Fdn Irccs Ist Nazl Tumori, Milan, Italy

Maio, M:
 Univ Siena, Siena, Italy

 Univ Hosp Siena, Ctr Immunooncol, Siena, Italy

Salvagni, S:
 IRCCS Azienda Osped Univ Bologna, Bologna, Italy

Gutiérrez-Calderon, V:
 Hosp Reg Univ Malaga, Malaga, Spain

Gonzalez-Cao, M:
 Hosp Univ Dexeus, Inst Oncol Dr Rosell IOR, Barcelona 08078, Spain

Contreras, SS:
 Inst Valenciano Oncol IVO, Valencia, Spain

Koumarianou, A:
 Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece

Bearz, A:
 IRCCS Ctr Riferimento Oncol, Aviano, Italy

Bernabé-Caro, R:
 Hosp Univ Virgen Rocio, Sevilla, Spain

Viteri, S:
 Clin Mi Tres Torres, UOMI Canc Ctr, Barcelona, Spain

de Sanmamed, MF:
 Clin Univ Navarra, Pamplona, Spain

Zagouri, F:
 Alexadra Gen Hosp Athens, Athens, Greece

:
 Hosp Univ Germans Trias & Pujol, ICO Badalona, Badalona, Spain

Lazzari, C:
 Ist Candiolo Fdn Piemonte Oncol IRCCS, Candiolo, Italy

Martínez-Recio, S:
 Hosp Santa Creu & St Pau, Barcelona, Spain

Giménez-Capitán, A:
 SA Hosp Univ Dexeus, Pangaea Oncol, Barcelona, Spain

Zhang, Y:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Shan, Y:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Zhu, HQ:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Zhao, CQ:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Shen, HG:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Wang, Y:
 GenFleet Therapeut Shanghai, Shanghai, Peoples R China

Rosell, R:
 Hosp Univ Dexeus, Inst Oncol Dr Rosell IOR, Barcelona 08078, Spain
ISSN: 14702045





LANCET ONCOLOGY
Editorial
The Lancet Publishing Group, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Reino Unido
Tipo de documento: Article
Volumen: 27 Número: 4
Páginas: 432-441
WOS Id: 001735009200001
ID de PubMed: 41926959

MÉTRICAS